Literature DB >> 35323932

Facilitating Safe Discharge Through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study to Develop and Validate a Clinical Prediction Model in Resource-Limited Settings.

Arjun Chandna1,2, Raman Mahajan3, Priyanka Gautam4, Lazaro Mwandigha5, Karthik Gunasekaran6, Divendu Bhusan7, Arthur T L Cheung2,8, Nicholas Day2,8, Sabine Dittrich2,9, Arjen Dondorp2,8, Tulasi Geevar10, Srinivasa R Ghattamaneni3, Samreen Hussain3, Carolina Jimenez3, Rohini Karthikeyan4, Sanjeev Kumar11, Shiril Kumar12, Vikash Kumar3, Debasree Kundu4, Ankita Lakshmanan3, Abi Manesh4, Chonticha Menggred8, Mahesh Moorthy13, Jennifer Osborn9, Melissa Richard-Greenblatt14, Sadhana Sharma15, Veena K Singh16, Vikash K Singh3, Javvad Suri3, Shuichi Suzuki17, Jaruwan Tubprasert8, Paul Turner1,2, Annavi M G Villanueva17, Naomi Waithira2,8, Pragya Kumar18, George M Varghese4, Constantinos Koshiaris5, Yoel Lubell2,8, Sakib Burza3,19.   

Abstract

BACKGROUND: In locations where few people have received coronavirus disease 2019 (COVID-19) vaccines, health systems remain vulnerable to surges in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Tools to identify patients suitable for community-based management are urgently needed.
METHODS: We prospectively recruited adults presenting to 2 hospitals in India with moderate symptoms of laboratory-confirmed COVID-19 to develop and validate a clinical prediction model to rule out progression to supplemental oxygen requirement. The primary outcome was defined as any of the following: SpO2 < 94%; respiratory rate > 30 BPM; SpO2/FiO2 < 400; or death. We specified a priori that each model would contain three clinical parameters (age, sex, and SpO2) and 1 of 7 shortlisted biochemical biomarkers measurable using commercially available rapid tests (C-reactive protein [CRP], D-dimer, interleukin 6 [IL-6], neutrophil-to-lymphocyte ratio [NLR], procalcitonin [PCT], soluble triggering receptor expressed on myeloid cell-1 [sTREM-1], or soluble urokinase plasminogen activator receptor [suPAR]), to ensure the models would be suitable for resource-limited settings. We evaluated discrimination, calibration, and clinical utility of the models in a held-out temporal external validation cohort.
RESULTS: In total, 426 participants were recruited, of whom 89 (21.0%) met the primary outcome; 257 participants comprised the development cohort, and 166 comprised the validation cohort. The 3 models containing NLR, suPAR, or IL-6 demonstrated promising discrimination (c-statistics: 0.72-0.74) and calibration (calibration slopes: 1.01-1.05) in the validation cohort and provided greater utility than a model containing the clinical parameters alone.
CONCLUSIONS: We present 3 clinical prediction models that could help clinicians identify patients with moderate COVID-19 suitable for community-based management. The models are readily implementable and of particular relevance for locations with limited resources.
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.

Entities:  

Keywords:  COVID-19; LMIC; low- and middle-income country; prognostic model; triage

Mesh:

Substances:

Year:  2022        PMID: 35323932      PMCID: PMC9129107          DOI: 10.1093/cid/ciac224

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  36 in total

1.  Calculating the sample size required for developing a clinical prediction model.

Authors:  Richard D Riley; Joie Ensor; Kym I E Snell; Frank E Harrell; Glen P Martin; Johannes B Reitsma; Karel G M Moons; Gary Collins; Maarten van Smeden
Journal:  BMJ       Date:  2020-03-18

2.  An inflammatory cytokine signature predicts COVID-19 severity and survival.

Authors:  Diane Marie Del Valle; Seunghee Kim-Schulze; Hsin-Hui Huang; Noam D Beckmann; Sharon Nirenberg; Bo Wang; Yonit Lavin; Talia H Swartz; Deepu Madduri; Aryeh Stock; Thomas U Marron; Hui Xie; Manishkumar Patel; Kevin Tuballes; Oliver Van Oekelen; Adeeb Rahman; Patricia Kovatch; Judith A Aberg; Eric Schadt; Sundar Jagannath; Madhu Mazumdar; Alexander W Charney; Adolfo Firpo-Betancourt; Damodara Rao Mendu; Jeffrey Jhang; David Reich; Keith Sigel; Carlos Cordon-Cardo; Marc Feldmann; Samir Parekh; Miriam Merad; Sacha Gnjatic
Journal:  Nat Med       Date:  2020-08-24       Impact factor: 53.440

3.  Pragmatic Recommendations for the Management of Acute Respiratory Failure and Mechanical Ventilation in Patients with COVID-19 in Low- and Middle-Income Countries.

Authors:  Ary Serpa Neto; William Checkley; Chaisith Sivakorn; Madiha Hashmi; Alfred Papali; Marcus J Schultz
Journal:  Am J Trop Med Hyg       Date:  2021-01-13       Impact factor: 2.345

4.  Validation of two multiplex platforms to quantify circulating markers of inflammation and endothelial injury in severe infection.

Authors:  Aleksandra Leligdowicz; Andrea L Conroy; Michael Hawkes; Kathleen Zhong; Gerald Lebovic; Michael A Matthay; Kevin C Kain
Journal:  PLoS One       Date:  2017-04-18       Impact factor: 3.240

5.  Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.

Authors:  Nikoletta Rovina; Karolina Akinosoglou; Jesper Eugen-Olsen; Salim Hayek; Jochen Reiser; Evangelos J Giamarellos-Bourboulis
Journal:  Crit Care       Date:  2020-04-30       Impact factor: 9.097

6.  Pragmatic Recommendations for Identification and Triage of Patients with COVID-19 in Low- and Middle-Income Countries.

Authors:  Lia M Barros; Jennifer L Pigoga; Sopheakmoniroth Chea; Bhakti Hansoti; Sarah Hirner; Alfred Papali; Kristina E Rudd; Marcus J Schultz; Emilie J Calvello Hynes
Journal:  Am J Trop Med Hyg       Date:  2021-01-06       Impact factor: 2.345

7.  Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Authors: 
Journal:  Lancet       Date:  2022-02-12       Impact factor: 79.321

8.  Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Authors: 
Journal:  Lancet       Date:  2021-05-01       Impact factor: 79.321

9.  Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

Authors:  Laure Wynants; Ben Van Calster; Gary S Collins; Richard D Riley; Georg Heinze; Ewoud Schuit; Marc M J Bonten; Darren L Dahly; Johanna A A Damen; Thomas P A Debray; Valentijn M T de Jong; Maarten De Vos; Paul Dhiman; Maria C Haller; Michael O Harhay; Liesbet Henckaerts; Pauline Heus; Michael Kammer; Nina Kreuzberger; Anna Lohmann; Kim Luijken; Jie Ma; Glen P Martin; David J McLernon; Constanza L Andaur Navarro; Johannes B Reitsma; Jamie C Sergeant; Chunhu Shi; Nicole Skoetz; Luc J M Smits; Kym I E Snell; Matthew Sperrin; René Spijker; Ewout W Steyerberg; Toshihiko Takada; Ioanna Tzoulaki; Sander M J van Kuijk; Bas van Bussel; Iwan C C van der Horst; Florien S van Royen; Jan Y Verbakel; Christine Wallisch; Jack Wilkinson; Robert Wolff; Lotty Hooft; Karel G M Moons; Maarten van Smeden
Journal:  BMJ       Date:  2020-04-07
View more
  1 in total

1.  Circulating suPAR associates with severity and in-hospital progression of COVID-19.

Authors:  Athanasios Chalkias; Anargyros Skoulakis; Nikolaos Papagiannakis; Eleni Laou; Konstantinos Tourlakopoulos; Athanasios Pagonis; Anastasia Michou; Nicoletta Ntalarizou; Maria Mermiri; Dimitrios Ragias; Enrique Bernal-Morell; Iria Cebreiros López; Luis García de Guadiana-Romualdo; Jesper Eugen-Olsen; Konstantinos Gourgoulianis; Ioannis Pantazopoulos
Journal:  Eur J Clin Invest       Date:  2022-05-04       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.